Stage 1: History of Biphasic Relapsing Cytopenias & Tick-Exposed Outdoor Lifestyle (Timestamp: 2 Weeks Prior to Admission)
A 30-year-old man (residing in Delhi NCR, restaurant cook / outdoorsman, history of alcohol-use disorder, peptic ulcer disease, Barrett's esophagus, anxiety) presents with a 2-week history of fatigue, exertional dyspnea, high fevers, night sweats, skin rash, and dark urine.
HPI:
- 3 Years Ago (Episode 1): Motor vehicle accident causing abdominal wall hematomas. 2 days later, developed acute severe thrombocytopenia (platelets 22,000/µL, down from 193,000/µL overnight!), moderate anemia (Hb 13.0 g/dL), and gross hematuria. Recovered spontaneously without plasma exchange and remained healthy for 3 years!
- Current Episode: 2 weeks of fatigue and panic-like palpitations; 5 days of high fevers (38.3°C) and night sweats; 3 days of an erythematous rash on the right knee and arm bruising. Removed a tick 2 weeks prior. Prescribed Doxycycline + Clindamycin + Quinine after Lyme serology screening was positive.
Hello, Chief Resident here.
Key Findings:
* Tick exposure with rash, fevers, night sweats, cytopenias (bruising, fatigue), and dark urine.
* Biphasic course: Acute severe drop in platelets/hemoglobin with dark urine 3 years prior (post-trauma), now relapsing.
* Positive Lyme serology; empirically started on Doxycycline/Clindamycin/Quinine.
Differential Diagnoses:
1. Babesiosis (± Lyme Co-infection) – 45%: Dark urine indicates intravascular hemolysis; key cause of tick-borne cytopenias.
2. Anaplasmosis / Ehrlichiosis – 25%: High fevers, marked cytopenias, tick vector; rash less common but possible.
3. Infection-Triggered TMA / Relapsing TTP – 15%: Explains sudden severe platelet drops, hemolysis, dark urine, and past episodic recurrence.
4. Relapsing Fever Borreliosis – 15%: Biphasic fevers, cytopenias, rash, and endemic exposure history.
Recommended Prioritized Tests:
1. Peripheral Blood Smear: Look for Babesia ring forms/Maltese cross, Anaplasma morulae, or schistocytes.
2. Tick-Borne Pathogen PCR Panel: Direct detection of Babesia, Anaplasma, Ehrlichia, and Borrelia DNA.
3. Hemolysis Workup: LDH, haptoglobin, indirect bilirubin, reticulocytes, direct Coombs test, and urine hemoglobin.
4. ADAMTS13 Activity Assay: Rule out acquired/congenital TTP given the biphasic hematologic drops.
5. Repeat CBC with Differential: Track severity of cytopenias.
Hello Attending Consultant here
Critique: Solid prioritization of smear/PCR/hemolysis labs, but underweights non-infectious mimics given biphasic post-trauma cytopenias + dark urine; empiric quinine risks cinchonism without confirmed Babesia; Lyme serology alone insufficient in endemic/non-endemic overlap (Delhi NCR). Add G6PD before quinine and hold plasma exchange pending ADAMTS13.
Top 3 DDx:
1. Babesiosis (tick + intravascular hemolysis + biphasic cytopenias)
2. Relapsing TTP/TMA (trauma-triggered sentinel episode, spontaneous recovery)
3. Anaplasmosis with secondary HLH-like features
Specific points:
1. Urgent smear for intraerythrocytic parasites/schistocytes before further abx.
2. Pair Babesia PCR with thick/thin films + IgM/IgG.
3. Full TMA panel: ADAMTS13, complement, homocysteine.
4. G6PD assay pre-quinine; switch to atovaquone-azithromycin if G6PD-def.
5. Quantify alcohol/PUD contribution to anemia (endoscopy if stable).
6. Repeat tick-borne serologies + blood cultures for Borrelia miyamotoi.
7. Hold clindamycin/quinine pending confirmatory parasitology.
Hello, Expert Clinician here.
Best unifying diagnosis: tick-borne Babesia infection causing intravascular hemolysis/cytopenias, possibly unmasking relapsing TMA/PNH. Fits: tick, fevers/sweats, bruising, dark urine; prior abrupt platelet crash after trauma may be a first complement/ADAMTS13 or PNH flare. Against pure babesiosis: Delhi NCR makes Lyme serology likely false-positive/cross-reactive; Babesia must be proven before quinine. Differentials: anaplasma/ehrlichia/rickettsiosis—fits tick, fever, cytopenias, but dark urine less typical; relapsing TTP/atypical HUS—fits biphasic thrombocytopenia/hemolysis and triggers, but spontaneous recovery argues for an infection trigger; PNH—fits dark urine/relapsing hemolysis, less the tick rash. Key pivot: prove whether urine is hemoglobin from parasites/PNH versus schistocyte TMA. Next move: urgent thick/thin smear, Babesia PCR, CBC/retic/LDH/haptoglobin/bilirubin/Coombs/urinalysis, ADAMTS13, complement and PNH flow cytometry, G6PD before quinine; continue doxycycline while confirming, PLEX only if severe ADAMTS13 deficiency/MAHA. Pearl: serology is a clue; smear plus hemolysis phenotype is the diagnosis.
Stage 2: Physical Exam & Severe Coombs-Negative MAHA with Severe Thrombocytopenia (Timestamp: Admission / Day 1)
Physical Exam: Temp 36.6°C, HR 88 bpm, BP 112/57 mmHg, RR 18/min, SpO2 99% on room air. Alert, oriented. Abdomen soft, non-tender, no hepatosplenomegaly. Skin: 6-cm blanching erythematous plaque in right popliteal fossa (erythema migrans) and 5-cm erythematous plaque near left patella with petechiae on left flank and arms.
Initial Laboratory Workup:
- CBC & Smear: WBC 9,000/µL (63% neutrophils, 5% bands, 5% metamyelocytes), Hemoglobin 5.8 g/dL (Hct 17.6%, MCV 94 fL), Platelets 15,000/µL (severe thrombocytopenia!). Reticulocytes 16.2% (marked reticulocytosis!). Smear: Occasional schistocytes (<1/hpf, rising to 2-3/hpf), no intraerythrocytic Babesia parasites.
- Chemistry & Urinalysis: Total Bilirubin 1.4 mg/dL, LDH 1,122 U/L, Haptoglobin UNDETECTABLE (<6 mg/dL), Ferritin 1,161 µg/L, D-Dimer 3,043 ng/mL. Creatinine 1.01 mg/dL (normal!). Fibrinogen 441 mg/dL, PT 13.4s (INR 1.1), aPTT 28.9s (normal PT/aPTT, ruling out DIC!). Direct Coombs test negative. Urinalysis: 2+ blood, 2+ protein, 20–50 RBCs/hpf.
Hello, Chief Resident here.
Updated Key Findings:
* Severe Coombs-negative MAHA (Hb 5.8 g/dL, LDH 1,122 U/L, haptoglobin <6, schistocytes) and severe thrombocytopenia (15,000/µL).
* Classic Erythema Migrans rash with normal renal function and normal PT/aPTT/fibrinogen (DIC excluded).
Differential Diagnoses:
1. Infection-Triggered TTP / TMA (50%): Extreme thrombocytopenia and MAHA with preserved renal function strongly suggest TTP, likely triggered by a tick-borne pathogen or prior trauma.
2. Anaplasmosis / Lyme Co-infection with Microangiopathic Cytopenias (25%): Confirmed EM rash; acute tick-borne illness driving secondary platelet/RBC destruction.
3. Complement-Mediated TMA (aHUS) (15%): Explains biphasic, trigger-happy (trauma, infection) Coombs-negative MAHA and thrombocytopenia.
4. Paroxysmal Nocturnal Hemoglobinuria (PNH) (10%): Biphasic intravascular hemolysis and cytopenias unmasked by acute infection.
Recommended Prioritized Tests:
1. STAT ADAMTS13 Activity & Inhibitor Screen: Critical to confirm TTP (<10% activity) and initiate plasma exchange (PLEX).
2. PNH Flow Cytometry (CD55/CD59): Rule out PNH clone.
3. Tick-Borne Pathogen PCR Panel: Direct detection of Borrelia, Anaplasma, Ehrlichia.
4. Complement Functional & Genetic Panel: Evaluate for alternative pathway dysregulation (aHUS).
5. G6PD Enzymatic Assay: Assess risk prior to oxidant antimicrobial therapies.
Hello Attending Consultant here
Critique: Overweights primary TTP given few schistocytes, preserved Cr, and clear EM; under-emphasizes smear-negative babesiosis (common early) and infection-driven secondary TMA. ADAMTS13 STAT is correct but pair with immediate empiric atovaquone-azithro while holding quinine; PLEX only if ADAMTS13 <10% + progressive MAHA.
Top 3 DDx:
1. Babesiosis ± Lyme (EM + intravascular hemolysis + TCP; smear can be negative)
2. Infection-triggered TTP/TMA (biphasic, trauma/tick triggers)
3. Anaplasmosis with secondary MAHA
Specific points:
1. Repeat thick/thin smears q12h + Babesia PCR/bloods.
2. Start atovaquone + azithromycin now; doxycycline for EM/Anaplasma coverage.
3. ADAMTS13 + inhibitor STAT; prepare but defer PLEX.
4. PNH flow + complement panel (C3/C4/AH50/genetic).
5. Transfuse RBCs/platelets judiciously; monitor for cardiac ischemia.
6. Serial LDH/haptoglobin/schistocyte counts + retic.
7. Hold quinine pending G6PD and parasitology confirmation.
Hello, Expert Clinician here.
Best unifying diagnosis now: babesiosis (smear-negative early), with Lyme EM and Coombs-negative intravascular hemolysis causing secondary TMA; tick-borne anaplasma is a close co-player. Fits: EM plaques, febrile sweats, haptoglobin zero, LDH high, urine heme-positive with RBCs, biphasic relapses. Less fitting: classic TTP usually has more schistocytes, neuro/renal change, and platelets this low can occur in babesiosis; aHUS/PNH can relapse with infection but EM is decisive for tick illness. DIC essentially excluded. Key pivot: separate parasite-driven hemolysis from ADAMTS13-deficient TMA before committing to PLEX. Next move: STAT ADAMTS13 activity/inhibitor, repeat thick/thin smears q12h plus Babesia microti/divergens PCR, Anaplasma/Ehrlichia/Borrelia PCR, PNH flow, complement C3/C4/AH50, G6PD; transfuse to symptomatic thresholds, monitor QT/hemolysis. Treat empirically for babesiosis/EM/anaplasma while results pend; reserve PLEX for ADAMTS13 <10% or worsening MAHA/neuro. Pearl: normal creatinine does not exclude babesiosis, and a negative first smear never rules it out.
Stage 3: Acute Neurologic Deficit & High-Risk PLASMIC Score (6/7) (Timestamp: Hospital Day 3)
Hospital Day 3 Event: Sudden onset of expressive aphasia, pronator drift of the right arm, and inability to follow complex commands (focal cerebral microthrombosis / transient ischemic attack!).
Neuroimaging: Emergency CT Angiography of head/neck revealed normal intracranial vessels without acute stroke or hemorrhage.
PLASMIC Risk Stratification:
- Severe thrombocytopenia (<30k): YES (+1)
- Hemolysis (Reticulocytes >2.5%, Haptoglobin <6): YES (+1)
- No active cancer: YES (+1)
- No transplant history: YES (+1)
- MCV <90 fL: NO (94 fL, 0)
- INR <1.5: YES (+1)
- Creatinine <2.0 mg/dL: YES (+1)
- Total PLASMIC Score = 6/7 (High Risk of Severe ADAMTS13 Deficiency <10%!).
Hello, Chief Resident here.
Updated Key Findings:
* New focal neurological deficits (expressive aphasia, right arm drift) indicating cerebral microvascular ischemia.
* High PLASMIC score (6/7) strongly predicting severe ADAMTS13 deficiency (<10%).
* Progression to classic TTP pentad (MAHA, severe thrombocytopenia, fever, neurological signs) triggered by tick-borne exposure.
Differential Diagnoses:
1. Thrombotic Thrombocytopenic Purpura (TTP - Infection/Tick-Triggered) – 75%: Acute neurologic compromise plus PLASMIC score 6/7 makes TTP the top, life-threatening diagnosis.
2. Severe Babesiosis / Anaplasmosis with Secondary TMA – 15%: Direct pathogen-driven endothelial damage and microvascular occlusion.
3. Complement-Mediated TMA (aHUS) – 10%: Infection-triggered alternative pathway dysregulation with extra-renal (neurologic) involvement.
Recommended Prioritized Actions & Tests:
1. Immediate Therapeutic Plasma Exchange (PLEX) + Corticosteroids (± Caplacizumab): Emergent initiation required; do not delay treatment while awaiting lab confirmation.
2. Brain MRI (DWI/FLAIR): Detect subtle microinfarcts or focal ischemia not visualized on CT.
3. Expedite ADAMTS13 Activity & Inhibitor Levels: Definitive diagnostic confirmation.
4. STAT Babesia & Anaplasma PCR: Rule out active infection driving or compounding the TMA.
5. Neuro-ICU Transfer: Intensive monitoring for progressive neurological decline or organ dysfunction.
Hello Attending Consultant here
Critique: Correctly escalates to empiric PLEX given PLASMIC 6/7 + focal neuro deficits, but over-commits to primary TTP (75%) while underweighting smear-negative babesiosis as TMA trigger; neuro events occur in both. Do not drop dual antimicrobial coverage or PNH/complement labs. Caplacizumab only post-ADAMTS13 confirmation.
Top 3 DDx:
1. Infection-triggered TTP (PLASMIC 6/7 + cerebral microthrombosis)
2. Severe babesiosis ± Lyme with secondary TMA
3. Anaplasmosis-driven TMA / aHUS overlap
Specific points:
1. Initiate PLEX + steroids immediately; add caplacizumab only if ADAMTS13 <10%.
2. Continue atovaquone-azithromycin + doxycycline through PLEX.
3. STAT ADAMTS13 activity/inhibitor + serial smears/Babesia PCR.
4. Urgent MRI brain (DWI) for microinfarct burden.
5. PNH flow cytometry + complement panel (C3/C4/AH50).
6. Neuro-ICU monitoring; avoid platelet transfusion unless life-threatening bleed.
7. Daily LDH/platelets/schistocytes to gauge PLEX response.
Hello, Expert Clinician here.
Best unifying diagnosis: acquired TTP with cerebral microthrombosis, plausibly triggered by tick-borne infection—especially babesiosis with Lyme/anaplasma co-exposure. The expressive aphasia and pronator drift with normal CTA fit microvascular TTP rather than large-vessel stroke. PLASMIC 6/7 makes severe ADAMTS13 deficiency likely, but it does not exclude infection-driven secondary TMA.
Differentials: severe babesiosis remains important because hemolysis, thrombocytopenia, fevers, and negative early smears fit; anaplasma/ehrlichia fits cytopenias and tick exposure but less well the MAHA; aHUS/PNH could relapse after infection, yet the neurologic event plus PLASMIC profile favors TTP.
Key pivot: new focal neurology converts this from “possible TMA” to a treat-first emergency.
Next move: obtain ADAMTS13 activity/inhibitor immediately, but start plasma exchange and corticosteroids without waiting; add caplacizumab once severe deficiency is confirmed. Continue tick-borne evaluation and empiric coverage, repeat smears/PCR, MRI-DWI, PNH flow, and complement studies. Avoid platelet transfusion unless life-threatening bleeding.
Pearl: in suspected TTP, neurologic change is the point where diagnostic certainty must never delay plasma exchange.
Stage 4: ADAMTS13 Biomarker Paradox & Genetic Sequencing (Timestamp: Hospital Days 4-6)
Emergency Intervention & Biomarker Paradox:
- Emergency Intervention: Daily Therapeutic Plasma Exchange (TPE) + IV Glucocorticoids initiated immediately. Aphasia and headache resolved after 1st/2nd TPE; platelets normalized after 3rd session. TPE stopped on Day 6 (ADAMTS13 activity recovered to 62%).
- Diagnostic Biomarker Discrepancy:
- ADAMTS13 Activity: <5% (severely deficient, confirming TTP!).
- ADAMTS13 Neutralizing Inhibitor Assay: <0.4 inhibitor units (NEGATIVE!).
- Anti-ADAMTS13 IgG Autoantibody ELISA: 56 arbitrary units (POSITIVE!).
Genetic Sequencing: Identified compound heterozygous pathogenic sequence variants in the ADAMTS13 gene (c.98delT [exon 1] and c.3178C->T [exon 24]), confirming underlying autosomal recessive inherited TTP.
Unifying Diagnosis: Combined Inherited (Upshaw-Schulman Syndrome) and Acquired Thrombotic Thrombocytopenic Purpura (TTP) — baseline partial congenital ADAMTS13 deficiency triggered into acute microvascular thrombosis by physiological stress (trauma 3 years prior) and tickborne infection (B. burgdorferi).
Hello, Chief Resident here.
Updated Key Findings:
* Severely deficient ADAMTS13 activity (<5%) with positive IgG autoantibodies.
* Genetic sequencing confirms compound heterozygous pathogenic ADAMTS13 variants (c.98delT / c.3178C->T).
* Rapid complete clinical/hematologic recovery post-TPE, confirming Upshaw-Schulman Syndrome (USS) unmasked by a secondary autoimmune flare and Borrelia burgdorferi infection.
Differential Diagnoses:
1. Congenital TTP (Upshaw-Schulman Syndrome) with Acquired Autoantibody Overlap & Tick Trigger – 85%: Confirmed by genetics; unifies the post-trauma sentinel episode and current tick-borne flare.
2. Primary Acquired Autoimmune TTP – 10%: Driven by IgG autoantibodies, though presence of dual pathogenic mutations overwhelmingly indicates underlying USS.
3. Infection-Induced Secondary TMA / aHUS Overlap – 5%: Excluded as primary driver given severe ADAMTS13 deficiency (<5%) and genetic diagnosis.
Recommended Next Steps:
1. Genetic Counseling & Cascade Screening: Evaluate first-degree relatives for ADAMTS13 mutations.
2. Long-Term Prophylaxis Planning: Evaluate for recombinant ADAMTS13 (Adzynma) or regular plasma infusions during high-risk stressors (infections, procedures).
3. Serial Biomarker Surveillance: Monitor ADAMTS13 activity and IgG autoantibody titers periodically.
4. Complete Antimicrobial Therapy: Ensure full eradication of Borrelia and tick-borne co-pathogens.
5. Patient Education: Issue medical alert branding and strict avoidance of unmonitored triggers.
Hello Attending Consultant here
Critique: Excellent integration of genetics confirming USS, but overstates "acquired autoantibody overlap" as primary driver—negative functional inhibitor with positive ELISA IgG suggests non-neutralizing Abs or assay artifact, not classic iTTP. Under-emphasizes need to exclude ongoing infection as residual trigger; prophylaxis planning is premature without baseline ADAMTS13 kinetics post-recovery. Rapid TPE response fits congenital more than pure acquired.
Top 3 DDx:
1. Congenital TTP (USS) unmasked by Borrelia stressor (genetics + biphasic triggers)
2. Hybrid congenital/acquired TTP (low activity + ELISA+ IgG)
3. Infection-triggered secondary TMA on USS background
Specific points:
1. Repeat ADAMTS13 activity/inhibitor/ELISA off TPE to establish true baseline.
2. Full tick-borne PCR/serologies to confirm Borrelia clearance; complete doxy course.
3. Cascade family screening + genetic counseling for ADAMTS13 variants.
4. Consider recombinant ADAMTS13 prophylaxis only for high-risk periods (infection/surgery).
5. Serial monitoring: ADAMTS13 q3-6mo + education on trigger avoidance.
6. PNH/complement recheck if hemolysis recurs off therapy.
7. Avoid empiric caplacizumab given negative inhibitor.
Hello, Expert Clinician here.
Best current unifying diagnosis: congenital TTP/Upshaw-Schulman syndrome with an acute flare triggered by physiologic stressors, most recently tick-borne infection. The biallelic pathogenic ADAMTS13 variants, prior trauma-provoked episode, severe deficiency, and rapid response to plasma replacement strongly fit.
The positive anti-ADAMTS13 IgG with a negative functional inhibitor should not be overcalled as acquired TTP; it may represent a non-neutralizing antibody or assay discordance. Acquired autoimmune TTP remains possible but is less supported. Infection-associated secondary TMA, atypical HUS, or PNH are much less likely given ADAMTS13 <5% and the genetic result.
Key pivot: the biomarker paradox—severe ADAMTS13 deficiency, negative inhibitor, positive ELISA, and compound heterozygous mutations—shifts the case from pure acquired TTP to inherited TTP with an environmental trigger.
Next move: repeat ADAMTS13 activity, inhibitor, and antibody testing after recovery/off TPE to establish baseline and antibody persistence; confirm tick-borne infection clearance, provide genetic counseling and family screening, and plan prophylactic ADAMTS13 replacement for future high-risk stressors.
Pearl: a positive antibody assay does not prove acquired TTP when functional inhibition is absent and pathogenic ADAMTS13 variants are present.
Stage 5: Early Relapse, Rituximab B-Cell Depletion & Long-Term FFP Prophylaxis (Timestamp: Follow-up & Discharge)
Early Relapse & Long-Term Management:
- Early Relapse Event: 14 Days post-TPE stop, platelet count dropped to 120,000/µL with ADAMTS13 activity falling again to <5%. Plasma infusions (without exchange) given for 3 days without platelet rise (confirming non-neutralizing clearance autoantibodies!). Single session of TPE boosted platelets to 200,000/µL.
- Long-Term Targeted Therapy & Prophylaxis:
- Initiated Rituximab 375 mg/m² weekly x 4 doses to clear the anti-ADAMTS13 IgG clearance autoantibodies, maintaining normal platelets and LDH.
- Established long-term prophylactic Fresh Frozen Plasma (FFP) infusions every 8 to 10 weeks (without exchange) to supply functional ADAMTS13 enzyme, preventing future stress-induced relapses.
Hello, Chief Resident here.
Updated Key Findings:
* Early relapse 14 days post-TPE (platelets 120,000/µL, ADAMTS13 <5%) refractory to simple FFP infusion, but responsive to TPE and Rituximab.
* Phenotype confirms non-neutralizing clearance autoantibodies accelerating enzyme destruction on a background of Upshaw-Schulman Syndrome (USS).
Differential Diagnoses:
1. Congenital TTP (USS) with Acquired Clearance Autoantibodies – 85%: Proven compound heterozygous variants (c.98delT/c.3178C->T) coupled with antibody-mediated clearance responsive to Rituximab.
2. Acquired Autoimmune TTP with Incidental ADAMTS13 Variants – 10%: Autoimmune behavior and relapse drive, though dual pathogenic mutations confirm inherited substrate.
3. Persistent Infection-Triggered Immune TMA – 5%: Unlikely primary cause following complete antimicrobial therapy and clear response to immunomodulation.
Recommended Next Steps:
1. Monitor ADAMTS13 & Peripheral B-Cells (CD19/CD20): Track autoantibody clearance and target B-cell depletion post-Rituximab.
2. Transition to Recombinant ADAMTS13 (Adzynma): Replace chronic FFP prophylaxis to minimize volume overload and transfusion-related risks.
3. Cascade Genetic Screening: Offer testing to first-degree relatives for the identified ADAMTS13 mutations.
4. Infection & Trigger Protocol: Provide emergency medical alert documentation and early-intervention protocols for future physiological triggers.
Hello Attending Consultant here
Critique: Correctly identifies clearance Abs driving early relapse on USS substrate and endorses rituximab + FFP, but overcalls “non-neutralizing” without pharmacokinetic data; under-emphasizes need for post-ritux ADAMTS13 kinetics before locking FFP interval. rADAMTS13 transition is preferred over chronic FFP.
Top 3 DDx:
1. USS + acquired clearance autoantibodies (genetics + ELISA+ + FFP-refractory relapse)
2. Hybrid congenital/acquired TTP
3. Residual infection-triggered immune clearance on USS background
Specific points:
1. Serial ADAMTS13 activity/ELISA + CD19 counts q4–6 wk post-rituximab to confirm B-cell depletion and Ab clearance.
2. Switch to recombinant ADAMTS13 (Adzynma) prophylaxis; reserve FFP for breakthrough only.
3. Pharmacokinetic study (pre/post-infusion ADAMTS13 half-life) to prove accelerated clearance.
4. Cascade family screening + genetic counseling.
5. Re-check tick-borne PCR/serologies; complete any residual antimicrobial course.
6. Medical-alert + trigger-action plan (infection/surgery → immediate plasma/rADAMTS13).
7. Avoid empiric caplacizumab given negative functional inhibitor.
Hello, Expert Clinician here.
Best unifying diagnosis: congenital TTP/Upshaw-Schulman syndrome with superimposed acquired anti-ADAMTS13 clearance autoantibodies, initially unmasked by trauma and later tick-borne infection. This best explains biallelic pathogenic variants, recurrent stress-provoked severe deficiency, positive IgG, early post-TPE relapse, and response to exchange plus B-cell depletion.
Key differentials: acquired autoimmune TTP with incidental variants—possible but less likely; inadequate replacement or ongoing consumption rather than true antibody-mediated clearance—requires pharmacokinetic confirmation; persistent infection or complement-mediated TMA—unlikely given the ADAMTS13 pattern and treatment response.
Key pivot: failure of plasma infusion alone but rapid response to TPE, suggesting accelerated antibody-mediated clearance rather than simple enzyme deficiency.
Next move: serial platelet/LDH, ADAMTS13 activity, antibody level, and B-cell recovery after rituximab; perform pre/post-infusion ADAMTS13 recovery and half-life testing to individualize prophylaxis. Prefer recombinant ADAMTS13 prophylaxis where available, reserving plasma for breakthrough episodes. Confirm infection clearance, provide family genetic screening, and establish an early-treatment plan for infection, surgery, pregnancy, or trauma.
Pearl: a negative functional inhibitor does not exclude clinically important clearance antibodies; enzyme recovery and half-life are decisive.